Read more

June 21, 2023
1 min read
Save

Top in endocrinology: Testosterone replacement; lower long COVID risk in metformin users

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In the TRAVERSE trial, men with hypogonadism at high risk for CVD who received testosterone had a similar risk for major adverse cardiovascular events compared with those who received placebo.

A. Michael Lincoff, MD, vice chair for research, cardiovascular medicine and professor of medicine at Cleveland Clinic, said during a presentation at ENDO 2023 that the findings “should facilitate more informed consideration of potential benefits and risks of testosterone treatment for middle-aged and older men with hypogonadism.” It was the top story in endocrinology last week.

Testosterone drawing Adobe
In the TRAVERSE trial, men with hypogonadism at high risk for CVD who received testosterone had a similar risk for major adverse cardiovascular events compared with those who received placebo. Image: Adobe Stock

Another top story was about data that showed metformin may reduce the risk for long COVID. Researchers found that the risk for long COVID was 41.3% lower in metformin users with overweight or obesity compared with placebo over a 10-month follow-up period.

Read these and more top stories in endocrinology below:

TRAVERSE: Men using testosterone replacement do not have increased risk for CV events

Older men with hypogonadism and high risk for cardiovascular disease who received testosterone therapy had similar rates of cardiovascular events as those who received placebo, according to findings from the TRAVERSE trial. Read more.

Metformin may reduce risk for long COVID among adults with obesity

Adults with overweight or obesity who received metformin shortly after a COVID-19 diagnosis had a lower risk for developing long COVID than those receiving placebo, according to study data. Read more.

Teriparatide delivered by robotic pill provides higher bioavailability than injection

An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023. Read more.

A coming ‘renaissance in endocrinology’: A conversation with R. Scott Struthers, PhD

R. Scott Struthers, PhD, had a lab job synthesizing peptide hormones as a college freshman. That experience launched a career featuring discovery of novel agents for endocrine diseases, women’s health conditions and cancers. Read more.

Combined exposures to environmental dioxins associated with hypothyroidism

Using three different statistical models, researchers determined that exposure to individual and a combination of 20 dioxins negatively affects thyroid function, according to a presenter at ENDO 2023. Read more.